About
Mary Spellman, MD, FAAD is a board-certified dermatologist and biotech drug-development executive focused on dermatology, rare disease, and age-related indications. She is Chief Medical Officer at Rubedo Life Sciences, a longevity-focused biotech developing therapies targeting pathological senescent cells. Previously she served as Chief Medical Officer at Castle Creek Biosciences, Menlo Therapeutics, and Revance Therapeutics, and earlier held dermatology research leadership roles at Biogen, Stiefel, and Novartis.
Areas of interest
longevitybiotechdermatologyclinical researchdrug developmentrare diseasesenotherapeuticsgene therapycell therapyimmunology